A carregar...
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. However,...
Na minha lista:
| Publicado no: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918267/ https://ncbi.nlm.nih.gov/pubmed/27508178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S45040 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|